Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study group.
Aged
Antineoplastic Agents
/ therapeutic use
Ascitic Fluid
/ pathology
Carcinoma, Ovarian Epithelial
/ genetics
Cohort Studies
Cytoreduction Surgical Procedures
Female
France
Genes, BRCA1
Genes, BRCA2
Humans
Lymph Node Excision
/ statistics & numerical data
Lymph Nodes
/ pathology
Middle Aged
Multivariate Analysis
Neoadjuvant Therapy
Neoplasm Invasiveness
Neoplasm Staging
Neoplasm, Residual
Omentum
/ pathology
Ovarian Neoplasms
/ genetics
Pelvis
Peritoneal Lavage
Platinum Compounds
/ therapeutic use
Prognosis
Proportional Hazards Models
Survival Rate
Taxoids
/ therapeutic use
Interval debulking surgery
Neoadjuvant chemotherapy
Ovarian cancer
Overall survival
Journal
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
31
01
2020
revised:
05
04
2020
accepted:
15
04
2020
pubmed:
18
5
2020
medline:
9
2
2021
entrez:
18
5
2020
Statut:
ppublish
Résumé
The aim of this study was to identify prognostic factors of overall survival in patients with FIGO stage IIIc or IVa ovarian cancer (OC) treated by neo-adjuvant chemotherapy (NAC) followed by interval debulking surgery. Data from 483 patients with ovarian cancer were retrospectively collected, from January 1, 2000 to December 31, 2016, from the FRANCOGYN database, regrouping data from 11 centers specialized in ovarian cancer treatment. Median overall survival was determined using the Kaplan-Meier method. Univariate and multivariate analysis were performed to define prognostic factors of overall survival. The median overall survival was 52 after a median follow up of 30 months. After univariate analysis, factors significantly associated with decreased overall survival were; no pelvic and/or para-aortic lymphadenectomy (p = 0.002), residual disease (CC1/CC2/CC3) after surgery (p < 0.001), positive cytology after NAC (p < 0.001), omental disease after NAC (p = 0.002), no pathologic complete response (pCR) (p = 0.002). In multivariate analysis, factors significantly associated with decreased overall survival were; residual disease after surgery (HR = 1.93; CI95% (1.16-3.21), p = 0.01) and positive cytology after NAC (HR = 1.59; CI95% (1.01-2.55), p = 0.05). Patients with no residual disease after surgery had a median overall survival of 64 months versus 35 months for patients with residual disease. Patients with negative cytology after NAC had a median overall survival of 71 months versus 43 months for patients with positive cytology after NAC. In this first and largest French based retrospective study, complete cytoreductive surgery in ovarian cancer remains the main prognostic factor of overall survival.
Identifiants
pubmed: 32417154
pii: S0748-7983(20)30426-1
doi: 10.1016/j.ejso.2020.04.029
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Platinum Compounds
0
Taxoids
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1689-1696Informations de copyright
Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest None.